NCT03550027

Brief Summary

Malignant pleural effusion (MPE) is a complication of almost any site of primary cancer as well as primary tumors of the pleura. Half of MPE patients have non-expendable trapped lungs not suitable for talc pleurodesis. Indwelling pleural catheters (IPCs), however, can be used in this cohort of patients, bringing about an improvement in dyspnea and quality of life (QOL). The aim of this study is to obtain pilot data - comparing patients receiving two different types of indwelling pleural catethers normally used in clinical practice (10 patients receiving Pleurocath® and 10 patients receiving PleurX®) - for power calculation of a Randomized Controlled Trial comparing two different drainages for MPE trapped lung.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Apr 2017

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 21, 2017

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 3, 2017

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 15, 2018

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

March 21, 2018

Completed
3 months until next milestone

First Posted

Study publicly available on registry

June 8, 2018

Completed
Last Updated

November 26, 2024

Status Verified

June 1, 2018

Enrollment Period

7 months

First QC Date

March 21, 2018

Last Update Submit

November 22, 2024

Conditions

Outcome Measures

Primary Outcomes (2)

  • Visual Analog Scale (VAS) range 0 (no pain) - 100 (maximum pain)

    Thoracic pain

    Post operative day 4th

  • Visual Analog Scale (VAS) range 0 (no dyspnea) - 100 (maximim dyspnea)

    Dyspnea

    Post operative day 4th

Study Arms (2)

PleurX

EXPERIMENTAL

Positioning of Pleurx drainage during surgical exploration if lung does not reinflate

Device: PleurX

Pleurocath

EXPERIMENTAL

Positioning of Pleur o cath drainage during surgical exploration if lung does not reinflate

Device: Pleurocath

Interventions

PleurXDEVICE

Positioning of drainage PleurX

PleurX

Positioning of drainage Pleurocath

Pleurocath

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult patients, with a clinical confident diagnosis of symptomatic malignant pleural effusion, enrolled for VATS exploration but not amenable of VATS talc poudrage because of trapped lung (patients with only partial expansion however receiving talc poudrage, but needing permanent pleural cathetes, are also eligible)

You may not qualify if:

  • \- Age younger than 18 years
  • Expected survival of less than 3 months
  • Chylothorax
  • Total white blood cell count less than 1000/microL
  • Pregnancy or lactating mothers
  • Irreversible bleeding diathesis
  • Irreversible visual impairment
  • Contraindications to general anesthesia
  • Poor general clinical conditions ( ECOG PS \>=2)
  • Patients unable to provide informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

European Institute of Oncology

Milan, 20141, Italy

Location

MeSH Terms

Conditions

Pleural Effusion

Condition Hierarchy (Ancestors)

Pleural DiseasesRespiratory Tract Diseases

Study Officials

  • Francesco Petrella, MD, PhD

    European Institute of Oncology

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 21, 2018

First Posted

June 8, 2018

Study Start

April 21, 2017

Primary Completion

November 3, 2017

Study Completion

February 15, 2018

Last Updated

November 26, 2024

Record last verified: 2018-06

Locations